JP Morgan scoops fees from Johnson & Johnson deal

JP Morgan is to be the only investment bank to benefit from the purchase of Scios by Johnson & Johnson, as the US healthcare giant snubbed Wall Street advice.

JP Morgan is sole adviser to Scios, the US biotechnology group, on the $2.4bn (€2.2bn) sale. The bank has twice previously managed equity financings for Scios, the most recent being a $150m convertible bond offering in August 2002.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump